Authorities Cited: United States Code 21 U.S.C. § 352(n) 28 U.S.C. § 1291 28 U.S.C. § 1331 28 U.S.C. § 1658(b) Code of Federal Regulations 21 C.F.R. § 202.1(e)(6) Supreme Court 455 U.S. 551, 556 485 U.S. 224, 231-232 501 U.S. 1083, 1095 Circuit Courts 725 F.2d 943, 944 766 F.2d 770, 776 841 F.2d 600, 607 857 F.2d 179, 185 868 F.2d 644, 645 991 F.2d 968, 980 54 F.3d 443, 444 113 F.3d 781, 786 114 F.3d 1410, 1425 115 F.3d 1332, 1335 154 F.3d 1191, 1196 175 F.3d 699, 705 226 F.3d 275, 282 244 F.3d 635, 639 260 F.3d 239, 241-254 306 F.3d 1314, 1318-1330 318 F.3d 148, 155 335 F.3d 187, 193-195 361 F.3d 44, 48 396 F.3d 161, 171 435 F.3d 396, 397-403 460 F.3d 494, 506-507 464 F.3d 634, 640 492 F.3d 209, 210-218 494 F.3d 956, 970 499 F.3d 239, 248-249 508 F.3d 170, 179 483 F. Supp. 2d 407, 419-425 975 F. Supp. 584, 599

Blogged: How Appealing Divided three-judge Third Circuit panel reinstates class action securities fraud complaint against Merck & Co alleging that the company misrepresented the safety profile and commercial viability of Vioxx